a_dose_of_drug_smallbanner_R2

Blog News - A Dose of Drug Development is a web publication produced by Integrium. The blog post content included conveys subjects of discussion and practice in the drug development process along with real-time Integrium activity. Readers interested in following are welcome to comment and interact on the Integrium website blog space.


Integrium, LLC Executives to Attend Ladenburg Thalmann Healthcare Conference, New York

By: Kevin Cho

Tustin, CA – Integrium, LLC Executives will be in New York during the Ladenburg Thalmann Healthcare Conference on October 2nd at the Sofitel New York. The Ladenburg Thalmann Healthcare Conference will feature presentations from CEOs and other thought leaders of an extensive range of life sciences companies across the biopharmaceutical and medical technology sectors and will include one-on-one meetings with investors.

Looking to meet with various types of organizations, Integrium typically engages in collaboration with startups and investors to discuss new business ventures and ways to work in partnerships. Attendees are encouraged to connect with Integrium for a brief introduction meeting during the conference and can request meeting time-slots by contacting Mike Loftus, Executive Director of Business Development to schedule: Mike.Loftus@integrium.com.


Integrium, LLC Executives to Attend Microcap Conference, New York

By: Kevin Cho

Tustin, CA – Integrium, LLC Executives will be in New York during the Microcap Conference on October 1st and 2nd at The Essex House overlooking Central Park. The MicroCap Conference will highlight the most attractive companies across various sectors, including many of the thought leaders in the biotechnology industry.

Looking to meet with various types of organizations, Integrium typically engages in collaboration with startups and investors to discuss new business ventures and ways to work in partnerships. Attendees are encouraged to connect with Integrium for a brief introduction meeting during the conference and can request meeting time-slots by contacting Mike Loftus, Executive Director of Business Development to schedule: Mike.Loftus@integrium.com.


Despite market volatility, 2018 has been on an astounding year for the biotech companies.

By: Kevin Cho

Despite market volatility, 2018 has been on an astounding year for the biotech companies. The landscape for initial public offerings (IPOs) has caught the attention of many. Particularly in Massachusetts, which has record 13 IPOs since the beginning of the year, raising a combined $1.3 billion. This in comparison to 2014 exceeds Massachusetts’ biotechs raising $1.2 BIL and the year is yet to be over.

Another exciting sector of biotech is the growth of digital health startups and the fields of incorporating artificial intelligence (A.I.) to its technology. As many have expected the epidemic of A.I. to cross over to biotech, it is likely that this will be a huge part of the industry in the near future. How Integrium as a company plays a role in advanced technology such as these is that Integrium has the advantage of having 20 years of experience with variety of therapies within its portfolio. Since A.I. is reliant on data, Integrium can provide this in volumes to increase accuracy and precision of the field of interest.

With the recent boom of biotech IPOs, one may argue that there have been a huge collective raise, but the number of companies is less than its previous year. Though 2017 may have had more IPOs in 9 months of the year, but the capital raise is considerably different. As stated by Forbes, venture capitalists invested about $10.6 billion into healthcare within the first half of 2018. Though the number of companies may be less, there have been a significant increase in investments in the biotech sector.

Alongside this enthusiasm in the biotech market, Integrium strives to collaborate and assist alongside some of the key players to bring their innovations to the market. As all signs are pointing to the continued growth in biotech market, Integrium will grow in parallel with this market growth.

Check out our new website!
www.integrium.com

To learn more about Integrium, contact:
Kevin Cho
Business Development Analyst
kevin.cho@integrium.com
714-591-0267


Integrium, LLC to Attend 20th Annual Global Investment

By: Kevin Cho

Tustin, CA - Integrium, LLC announced they will be attending the 20th Annual Global Investment sponsored by H.C. Wainwright & Co. on September 4-6 at St. Regis, New York, NY. Integrium is looking forward to joining other industry thought leaders and pharmaceutical companies in the Microcap space to fulfill networking goals and potential partnerships.

This event will allow gain of exposure to new and existing Microcap companies. Integrium helps Biotechnology, Pharmaceutical, and Medical Device companies to conserve cash and gain an additional shot-on-goal while waiting for larger ongoing clinical trials to complete.

Integrium Executives will be taking meetings throughout the event and encourage guests to schedule meeting requests with Mark Powers, Executive Director of Capital Solutions. Please contact kevin.cho@integrium.com to schedule time with Integrium during the event.

About Integrium

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Innovator and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.

Check out our new website!
www.integrium.com

To learn more about Integrium, contact:
Kevin Cho
Business Development Analyst
kevin.cho@integrium.com
714-591-0267


Integrium, LLC to Attend the 2018 Biotechnology Innovation Organization (BIO) International Convention located in Boston, CA

By: Kevin Cho

Tustin, CA - Integrium, LLC announced they will be attending the 2018 Biotechnology Innovation Organization (BIO) International Convention located in Boston, CA on June 4-6. Integrium is looking forward to joining other industry thought leaders and pharmaceutical companies to fulfill networking goals and potential partnerships.

The key benefits of attending the BIO International Convention is to gain exposure to biotechnology and pharmaceutical leaders and opportunities to network with 16,000+ attendees from 74 countries. For more information, or to register, please see BIO’s website (http://convention.bio.org/)

Integrium Executives will be taking meetings throughout BIO and encourage guests to schedule meeting requests with Mike Loftus, Executive Director of Business Development and other companies attending BIO. Please contact kevin.cho@integrium.com to schedule time with Integrium during BIO.

About Integrium

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Innovator and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.

Check out our new website!

www.integrium.com

To learn more about Integrium, contact:

Kevin Cho
Business Development Analyst
kevin.cho@integrium.com
714-591-0267


Staying on track for 2017 year end enrollment goals?

By: Emily MacHale

Sponsor s come to Or ange County Resea r ch Center (OCRC) because:

  • They are struggling to meet enrollment projection and goals.
  • They are frustrated by the lack of urgency of current clinical sites.
  • They are upset that their study is not a priority at the site level.
  • They are excited by the large database of patients in a vast population center, such as Irvine, CA.

Upcoming New Year

With the end of 2017 in clear view, many biotechs are struggling with their studies and their ability to enroll patients on time. Often times, biotechs are in need of a little push to meet or exceed their enrollment goals to prepare for a successful and innovative new year. What are the strategies your biotech takes to ensure enrollment goals and timelines are achieved? What are the current enrollment struggles and what have you done to ensure patients are enrolled on time?

Sponsors typically go to Orange County Research Center (OCRC), Integrium’s Phase I-IV clinical unit, as a rescue site when they are needing one-on-one, relationship oriented guidance and are under pressure to meet their timelines.

a

About OCRC

Orange County Research Center, located in Tustin, CA, is a private medical facility which treats patients in clinical trials for Sponsors. OCRC recruits, manages, and executes cutting edge clinical research protocols for pharmaceutical and biotechnology companies. Some areas of focus are Cardiovascular Disease, Diabetes, Renal, Hypertension, Pain, Dermatology, and Wound Healing. OCRC, founded in 1985, has participated in over 450 clinical trials that have advanced the development of many new treatments.

Dr. Joel Neutel, OCRC’s Medical Director, has served as a Principal Investigator on several hundred-multinational cardiovascular, metabolic, dermatology and wound healing trials. He also carries with him extensive experience serving the biopharmaceutical industry in the areas of clinical and academic research, as well as marketing strategic planning.

b

Are you a Sponsor in need of an OCRC-type relationship? For more information regarding OCRC’s vision and initiatives, contact Mike Loftus, Executive Director of Business Development at Mike.Loftus@integrium.com.